26.87 USD
↗ 0.53 (2.01%)AT CLOSE (11:59 AM EDT)
Bicara Therapeutics Inc. Common Stock
BCAXNASDAQ • USD
26.85
↘ 0.02 (0.07%)
POST MARKET (AS OF 04:36 PM EDT)
Post Market
AS OF 04:36 PM EDT
26.85
↘ 0.02 (0.07%)
Market: CLOSED
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $26.87. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, BCAX trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 26, 2026.
Open?$26.30
High?$27.00
Low?$26.02
Prev. Close?$26.34
Volume?4.6M
Avg. Volume?760.7K
VWAP?$26.62
Rel. Volume?6.05x
Bid / Ask
Bid?$20.25 × 100
Ask?$29.00 × 700
Spread?$8.75
Midpoint?$24.63
Valuation & Ratios
Market Cap?1.8B
Shares Out?65.7M
Float?50.7M
Float %?77.2%
P/E Ratio?N/A
P/B Ratio?3.44
EPS?-$2.39
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Themes
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?25.73Safe
Confidence?41%Low
Short InterestSqueeze Risk
Short % of Float?20.03%Squeeze Risk
Short Interest?10.2M
Days to Cover?19.8
Free Float50.7M
Avg Daily Volume514.1K
Settlement Date2026-06-15
Financial Health
Current Ratio?13.85Strong
Quick Ratio?13.85Strong
Cash Ratio?8.22Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.44FAIR▾
Peers100
S&P49
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-8.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-30.6%WEAK▾
S&P6
ROA?-28.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-116576000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day